Table 3.

Serum IgM and IgG anti-LPS titers of vaccinees

ImmunogennGM ELISA titera (25th–75th centiles) at indicated day postinjection
0 (preinjection)2842b70230
IgM
 DeALPS-CT-1191.9 (0.9–3.9)10.6 (3.6–35)8.5 (3.4–31)8.4 (4.0–29)13.7 (4.0–31)
 DeALPS-CT-2191.3 (1.0–2.5)17.4 (6.9–52)14.2 (5.4–38)12.5 (5.3–30)12.0 (6.0–24)
 DeALPS191.1 (0.8–1.7)1.1 (1.0–2.5)1.2 (0.7–2.6)1.7 (0.9–3.2)4.6 (3.3–7.7)
 Cellularc 181.6 (1.0–4.0)19.2 (9.6–39)16.0 (7.4–26)15.3 (8.7–36)16.9 (8.4–29)
IgG
 DeALPS-CT-1192.8 (0.8–7.1)7.2 (1.3–30)7.1 (1.3–49)7.2 (1.0–29)3.4 (0.7–4.0)
 DeALPS-CT-2191.8 (0.7–4.4)14.3 (0.7–124)18.2 (5.8–120)17.6 (4.2–82)5.1 (1.3–29)
 DeALPS192.1 (0.9–4.8)2.9 (1.1–6.8)3.3 (1.1–10)2.1 (0.8–6.7)0.8 (0.4–1.6)
 Cellular182.2 (0.8–5.8)4.9 (1.1–18)4.8 (1.2–26)5.9 (1.7–24)3.4 (1.6–5.3)
  • a Expressed as percentage of a reference serum (M&M) assigned a value of 100. Post- versus prevaccination sera from vaccinees injected with the two conjugates and the cellular vaccine had higher GM levels (P < 0.001); there was no statistically significant difference between the postvaccination levels of the three groups at any interval. For recipients of DeALPS alone, 4.6 versus 1.1, P = 0.0001. For IgG, 14.3 versus 4.9 and 17.6 versus 5.9, P = 0.05; 18.2 versus 4.8,P = 0.03; 5.1 versus 3.4, P = NS.

  • b Blood sample taken and reinjected with same vaccine.

  • c Wyeth-Ayerst Laboratories, 4 × 109 organisms each of V. cholerae O1 serotypes Inaba and Ogawa.